- $16.73bn
- $25.19bn
- $2.35bn
- 86
- 52
- 71
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.16 | ||
| PEG Ratio (f) | 0.29 | ||
| EPS Growth (f) | 32.88% | ||
| Dividend Yield (f) | 3.27% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.56 | ||
| Price to Tang. Book | 2.56 | ||
| Price to Free Cashflow | 19.18 | ||
| Price to Sales | 7.11 | ||
| EV to EBITDA | 16.88 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.2% | ||
| Return on Equity | 18.67% | ||
| Operating Margin | 63.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,814.25 | 2,122.35 | 2,289.46 | 2,237.22 | 2,354.55 | 2,602.85 | 2,851.13 | 5.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +70.46 | -55.72 | -14.46 | +0.66 | +68.48 | +50.1 | +8.86 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Directors
- Pablo Legorreta CHM (57)
- Christopher Hite VCH (54)
- Terrance Coyne CFO (39)
- George Lloyd EVP (62)
- James Reddoch EVP (51)
- Molly Chiaramonte SVP
- Marshall Urist SVP
- Henry Fernandez LED (62)
- M. Germano Giuliani DRC (49)
- Rory Riggs DRC (68)
- Bonnie Bassler IND (58)
- Errol De Souza IND (67)
- Catherine Engelbert IND (56)
- William Ford IND (59)
- Ted Love IND (62)
- Gregory Norden IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 6th, 2020
- Public Since
- June 16th, 2020
- No. of Shareholders
- 4
- No. of Employees
- 89
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 597,484,791
- Address
- 110 East 59th Street, NEW YORK, 10022
- Web
- https://www.royaltypharma.com/
- Phone
- +1 2128830200
- Auditors
- Ernst & Young
Upcoming Events for RPRX
Q1 2024 Royalty Pharma PLC Earnings Release
Dividend For RPRX.OQ - 0.2100 USD
Royalty Pharma PLC Annual Shareholders Meeting
Q2 2024 Royalty Pharma PLC Earnings Release
Similar to RPRX
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Royalty Pharma share price?
As of Today at 19:18 UTC, shares in Royalty Pharma are trading at $28.00. This share price information is delayed by 15 minutes.
How has the Royalty Pharma share price performed this year?
Shares in Royalty Pharma last closed at $28.00 and the price had moved by -20.77% over the past 365 days. In terms of relative price strength the Royalty Pharma share price has underperformed the S&P500 Index by -35.23% over the past year.
What are the analyst and broker recommendations for Royalty Pharma?
The overall consensus recommendation for Royalty Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Royalty Pharma dividend yield?
The Royalty Pharma dividend yield is 2.86% based on the trailing twelve month period.
Does Royalty Pharma pay a dividend?
Last year, Royalty Pharma paid a total dividend of $0.80, and it currently has a trailing dividend yield of 2.86%.Looking ahead, shares in Royalty Pharma are due to go ex-dividend on 2024-05-16 and the next dividend pay date is 2024-06-14.
When does Royalty Pharma next pay dividends?
Royalty Pharma are due to go ex-dividend on 2024-05-16 and the next dividend pay date is 2024-06-14. The historic dividend yield on Royalty Pharma shares is currently 2.86%.
How do I buy Royalty Pharma shares?
To buy shares in Royalty Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Royalty Pharma?
As of the previous close price of $28.00, shares in Royalty Pharma had a market capitalisation of $16.73bn.
Where are Royalty Pharma shares listed?
Here are the trading details for Royalty Pharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RPRX
What kind of share is Royalty Pharma?
Based on an overall assessment of its quality, value and momentum Royalty Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Royalty Pharma share price forecast for 2024?
The analyst consensus target price for shares in Royalty Pharma is $45.50. That is 62.5% above the last closing price of $28.00.
Analysts covering Royalty Pharma currently have a consensus Earnings Per Share (EPS) forecast of $3.80 for the next financial year.
What is the trend in the Royalty Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Royalty Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -12.72%.
As of the last closing price of $28.00, shares in Royalty Pharma were trading -2.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Royalty Pharma PE Ratio?
The Royalty Pharma PE ratio based on its reported earnings over the past 12 months is 7.16. The shares last closed at $28.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Royalty Pharma?
Royalty Pharma's management team is headed by:
- Pablo Legorreta - CHM
- Christopher Hite - VCH
- Terrance Coyne - CFO
- George Lloyd - EVP
- James Reddoch - EVP
- Molly Chiaramonte - SVP
- Marshall Urist - SVP
- Henry Fernandez - LED
- M. Germano Giuliani - DRC
- Rory Riggs - DRC
- Bonnie Bassler - IND
- Errol De Souza - IND
- Catherine Engelbert - IND
- William Ford - IND
- Ted Love - IND
- Gregory Norden - IND